Payment overview · 2025
General Payments
$331.75
14 reported records · 12 companies
Healthcare provider profile · identity verified
Sarah Chae, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RIVERSIDE, CA · NPI 1003872169
Verified facts
What the public records show
CMS Open Payments records show Sarah Chae, MD received $331.75 in general payments during 2025 across 14 reported records.
Biogen, Inc. accounted for 13.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biogen, Inc. | Unresolved — no canonical attribution shown | $45.34 | 13.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.54 | 13.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $42.55 | 12.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.66 | 9.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.71 | 7.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.42 | 7.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.23 | 7.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.40 | 6.8% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.00 | 6.6% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $19.66 | 5.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.91 | 5.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.33 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $331.75 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $45.34 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.54 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $42.55 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $32.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| MYOSURE TISSUE REMOVAL DEVICE Normalized: myosure tissue removal device |
Device | Hologic Sales and Service, LLC | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 188 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
188 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 267 | 77 |
| Ozempic | Semaglutide | 188 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 66 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 177 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 56 |
| Losartan Potassium | Losartan Potassium | 164 | 52 |
| Trazodone Hcl | Trazodone Hcl | 138 | 43 |
| Gabapentin | Gabapentin | 134 | 49 |
| Lisinopril | Lisinopril | 121 | 43 |
| Metformin Hcl Er | Metformin Hcl | 109 | 41 |
| Omeprazole | Omeprazole | 106 | 40 |
| Carvedilol | Carvedilol | 99 | 30 |
| Eliquis | Apixaban | 97 | 22 |
| Azelastine Hcl | Azelastine Hcl | 91 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 27 |
| Simvastatin | Simvastatin | 85 | 21 |
| Valsartan | Valsartan | 85 | 27 |
| Metformin Hcl | Metformin Hcl | 78 | 26 |
| Meloxicam | Meloxicam | 77 | 27 |
| Montelukast Sodium | Montelukast Sodium | 77 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 23 |
| Jardiance | Empagliflozin | 71 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 18 |
| Atenolol | Atenolol | 67 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 30 |
| Sertraline Hcl | Sertraline Hcl | 63 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 16 |
| Baclofen | Baclofen | 57 | 21 |
| Bupropion Xl | Bupropion Hcl | 57 | 14 |
| Alendronate Sodium | Alendronate Sodium | 56 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 12 |
| Ibuprofen | Ibuprofen | 53 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 51 | 16 |
| Furosemide | Furosemide | 50 | 17 |
| Ezetimibe | Ezetimibe | 48 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 16 |
| Celecoxib | Celecoxib | 41 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 14 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Glipizide Er | Glipizide | 40 | 13 |
| Alprazolam | Alprazolam | 39 | 16 |
| Allopurinol | Allopurinol | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 14 |
| Synthroid | Levothyroxine Sodium | 35 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 16 |
| Methylprednisolone | Methylprednisolone | 33 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 26 |
| Famotidine | Famotidine | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Mupirocin | Mupirocin | 29 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Estradiol | Estradiol | 23 | 11 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | 11 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Prednisone | Prednisone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Diazepam | Diazepam | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $331.75 · 14 records | Biogen, Inc. | ABRYSVO, AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, FREESTYLE LIBRE 3, GARDASIL 9, MYFEMBREE, MYOSURE TISSUE REMOVAL DEVICE, Ozempic, Rybelsus, TREMFYA, UBRELVY, WaveWriter Alpha Prime 16, ZURZUVAE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error